Predictive Oncology (NASDAQ:POAI) Share Price Passes Below Two Hundred Day Moving Average of $3.13

Posted by Maddie Sorensen on Mar 28th, 2024

Predictive Oncology Inc. (NASDAQ:POAI – Get Free Report) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $3.13 and traded as low as $2.57. Predictive Oncology shares last traded at $2.78, with a volume of 9,915 shares changing hands.

Predictive Oncology Price Performance

The stock has a market capitalization of $11.29 million, a price-to-earnings ratio of -0.60 and a beta of 1.30. The business’s fifty day moving average price is $2.99 and its 200-day moving average price is $3.13.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Carnegie Mellon University acquired a new position in shares of Predictive Oncology during the fourth quarter valued at about $34,000. Charles Schwab Investment Management Inc. bought a new position in shares of Predictive Oncology during the first quarter valued at about $54,000. Renaissance Technologies LLC lifted its position in shares of Predictive Oncology by 26.9% during the fourth quarter. Renaissance Technologies LLC now owns 302,724 shares of the medical instruments supplier’s stock valued at $93,000 after purchasing an additional 64,261 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Predictive Oncology during the first quarter valued at about $66,000. Finally, Raymond James & Associates bought a new position in shares of Predictive Oncology during the third quarter valued at about $378,000. 9.04% of the stock is currently owned by institutional investors and hedge funds.

Predictive Oncology Company Profile

(Get Free Report)

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.